Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York, NY.

Key details of Apollomics' participation include:

• An on-demand company presentation available from September 9, 2024, at 7:00 am ET
• Presenters: Guo-Liang Yu, PhD (Chairman and CEO) and Matthew Plunkett, PhD (CFO)
• Management will be available for virtual one-on-one meetings
• The presentation will be accessible on the company's website

Apollomics focuses on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers.

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 26th Annual Global Investment Conference
Format: Company presentation
Presentation Date & Time: Available on demand as of September 9, 2024 at 7:00 am ET
Presenters: Guo-Liang Yu, PhD, Chairman and Chief Executive Officer and Matthew Plunkett, PhD, Chief Financial Officer
Webcast: Click here

Management will be available for virtual one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request meetings. The Company’s current presentation may be accessed on the Company website on the Events page under the Investors section.

About Apollomics Inc. 

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ programs include its lead product candidate, vebreltinib, a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort global clinical trial, and uproleselan, a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in a Phase 3 clinical trial in China. For more information, please visit www.apollomicsinc.com.

Investor Contact:

Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
eric@lifesciadvisors.com 

FAQ

When is Apollomics (APLM) presenting at the H.C. Wainwright Global Investment Conference?

Apollomics (APLM) will have an on-demand presentation available starting September 9, 2024, at 7:00 am ET as part of the H.C. Wainwright 26th Annual Global Investment Conference.

Who will be presenting for Apollomics (APLM) at the investment conference?

Guo-Liang Yu, PhD, Chairman and Chief Executive Officer, and Matthew Plunkett, PhD, Chief Financial Officer, will be presenting for Apollomics (APLM) at the H.C. Wainwright conference.

Where can investors access Apollomics' (APLM) presentation from the H.C. Wainwright conference?

Investors can access Apollomics' (APLM) presentation on the company's website on the Events page under the Investors section.

What type of cancer treatments is Apollomics (APLM) developing?

Apollomics (APLM) is developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers.

Will Apollomics (APLM) management be available for meetings during the conference?

Yes, Apollomics (APLM) management will be available for virtual one-on-one meetings during the H.C. Wainwright conference. Interested investors should contact their H.C. Wainwright representative to request meetings.